- Published on
KembaraXtra- Medicine- Aplastic Anemia
Aplastic anemia (AA) is a bone marrow failure syndrome caused by immune-mediated destruction of hematopoietic cells, leading to peripheral blood pancytopenia. Severe aplastic anemia (SAA) is diagnosed when at least two of the following are present: neutrophils <0.5 × 10⁹ />, platelets <20 × 10⁹ />, or corrected reticulocyte count <1%. aa is also called aplastic anemia, refractory or hypoplastic anemia. icd-10cm codes include d61.9 (aplastic unspecified), d60.9 />60.8 (acquired pure red cell aplasia), D61.09 (constitutional aplastic anemia), D61.1 (drug-induced), D61.2 (due to other external agents), D61.3 (idiopathic), and D61.89 (other specified aplastic anemias/bone marrow failure syndromes).
Epidemiologically, aplastic anemia is rare, with an annual incidence of about 2 cases per million in Western populations and 4–6 cases per million in Asia. It has a bimodal age distribution, with peaks in ages 15–30 and after age 60, and affects both sexes. Clinically, symptoms reflect the degree of cytopenias: anemia causes fatigue, pallor, exertional dyspnea, and palpitations; thrombocytopenia causes mucosal bleeding, easy bruising, petechiae, and heavy menstrual bleeding; and neutropenia may lead to fever and sore throat, although infection is often not prominent at initial presentation unless neutropenia is severe. Congenital forms may show features such as short stature and skeletal or nail abnormalities.
Most cases of idiopathic aplastic anemia result from immune (lymphocyte-mediated) destruction of bone marrow stem/progenitor cells. Some cases involve telomere biology: mutations affecting telomerase (e.g., TERT) can cause short telomeres in congenital aplastic anemia and in some apparently acquired marrow failure; telomere length in SAA treated with immunosuppressive therapy (IST) is not tied to response but is associated with relapse risk, clonal evolution, and survival. Acquired AA may be triggered by toxins (notably benzene and insecticides), drugs (examples include felbamate, cimetidine, NSAIDs, antiepileptics, gold salts, chloramphenicol, sulfonamides, trimethadione, quinacrine, phenylbutazone), ionizing radiation, and viral infections (including hepatitis viruses, HIV, EBV, and parvovirus B19). AA can also occur in association with conditions such as PNH, immune diseases (eosinophilic fasciitis, hyperimmunoglobulinemia), thymoma/thymic carcinoma, graft-versus-host disease in immunodeficiency, and pregnancy. Inherited marrow failure syndromes include Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, reticular dysgenesis, amegakaryocytic thrombocytopenia, familial aplastic anemias, and other nonhematologic syndromes (e.g., Down syndrome).
Diagnosis requires excluding other causes of pancytopenia and hypocellular marrow. Important differentials include bone marrow infiltration (lymphoma, carcinoma), myelofibrosis, severe infection, hypoplastic myelodysplastic syndrome, hypersplenism, and hairy cell leukemia. Workup centers on CBC with peripheral smear and bone marrow aspiration/biopsy, which typically shows a hypocellular marrow with marked reduction or absence of hematopoietic precursor cells; in pure red cell aplasia, only erythroid precursors are absent. Laboratory evaluation usually demonstrates pancytopenia, sometimes with macrocytosis and toxic granulation; early disease may show isolated cytopenias. Reticulocytopenia is common. Additional labs include LDH and haptoglobin to assess for hemolysis, nutritional studies (B12, folate, copper, zinc, ferritin) to rule out deficiencies, and viral serologies (hepatitis A/B/C, HIV, CMV, parvovirus, EBV) to identify contributory infections and guide management. Peripheral blood flow cytometry is used to rule out PNH. Imaging is not routinely required, but MRI (spin-echo) can show the high fat content of aplastic marrow and may be helpful in evaluating marrow disease.
Management begins with nonpharmacologic measures, especially stopping any suspected offending drugs or exposures. Acute care focuses on complications: neutropenic fever requires prompt empiric broad-spectrum antibiotics, and cytopenias are supported with platelet and PRBC transfusions as needed. In patients who may undergo allogeneic stem cell transplantation, frequent transfusions should be minimized when possible to reduce alloimmunization risk. Chronic management depends on severity: some patients can be observed with supportive care, but transfusion dependence or meeting SAA criteria requires definitive therapy, and HLA typing should be done early once SAA is confirmed.
Definitive therapy for SAA is either immunosuppressive therapy (IST) or allogeneic stem cell transplantation (SCT), chosen based on age, donor availability, comorbidities, and response. Traditionally, patients <40 years are treated with upfront allogeneic sct, while those>40 years start with IST; patients over 40 may proceed to SCT if there is suboptimal IST response after ~4 months. HLA-matched sibling donor SCT is potentially curative. For those without a matched sibling, IST has been standard, but newer evidence supports earlier use of matched unrelated donor (MUD) or haploidentical donor transplantation in selected patients, with haploidentical approaches using post-transplant cyclophosphamide offering the potential for reduced GVHD and infections. Standard IST in patients <60 years commonly uses antithymocyte globulin (atg) plus cyclosporine, with atg reserved for fitter older patients lower comorbidity burden. ist is now routinely combined eltrombopag (an oral thrombopoietin receptor agonist) to improve platelet recovery in newly diagnosed patients. hematopoietic growth factors such as g-csf have not shown improved survival even long-term follow-up. who fail initial may proceed allogeneic sct or receive alternative immunosuppression alemtuzumab; other agents like corticosteroids and cyclophosphamide supportive roles, androgens (e.g., danazol) can be effective second-line options.< />pan>
Prognosis has improved substantially with modern therapy. Reported outcomes show 10-year survival after SCT (2000–2010 cohort) around 86% (<20 years), 76% (21-40 and 55% (>40 years). Newer transplant data also suggest improved survival in patients >50 years, especially with good performance status and matched sibling donors, though patients >65 years have higher rates of severe GVHD. With IST alone, about 50% achieve long-term remissions without relapse, but 10–20% may develop clonal evolution to secondary myelodysplasia or acute myeloid leukemia over ~10 years. Because transplant outcomes continue to improve, earlier use of SCT is increasingly recommended for more patients when feasible. All patients with suspected or confirmed aplastic anemia should be referred to hematology.
Aplastic anemia (AA) is a bone marrow failure syndrome caused by immune-mediated destruction of hematopoietic cells, leading to peripheral blood pancytopenia. Severe aplastic anemia (SAA) is diagnosed when at least two of the following are present: neutrophils <0.5 × 10⁹ />, platelets <20 × 10⁹ />, or corrected reticulocyte count <1%. aa is also called aplastic anemia, refractory or hypoplastic anemia. icd-10cm codes include d61.9 (aplastic unspecified), d60.9 />60.8 (acquired pure red cell aplasia), D61.09 (constitutional aplastic anemia), D61.1 (drug-induced), D61.2 (due to other external agents), D61.3 (idiopathic), and D61.89 (other specified aplastic anemias/bone marrow failure syndromes).
Epidemiologically, aplastic anemia is rare, with an annual incidence of about 2 cases per million in Western populations and 4–6 cases per million in Asia. It has a bimodal age distribution, with peaks in ages 15–30 and after age 60, and affects both sexes. Clinically, symptoms reflect the degree of cytopenias: anemia causes fatigue, pallor, exertional dyspnea, and palpitations; thrombocytopenia causes mucosal bleeding, easy bruising, petechiae, and heavy menstrual bleeding; and neutropenia may lead to fever and sore throat, although infection is often not prominent at initial presentation unless neutropenia is severe. Congenital forms may show features such as short stature and skeletal or nail abnormalities.
Most cases of idiopathic aplastic anemia result from immune (lymphocyte-mediated) destruction of bone marrow stem/progenitor cells. Some cases involve telomere biology: mutations affecting telomerase (e.g., TERT) can cause short telomeres in congenital aplastic anemia and in some apparently acquired marrow failure; telomere length in SAA treated with immunosuppressive therapy (IST) is not tied to response but is associated with relapse risk, clonal evolution, and survival. Acquired AA may be triggered by toxins (notably benzene and insecticides), drugs (examples include felbamate, cimetidine, NSAIDs, antiepileptics, gold salts, chloramphenicol, sulfonamides, trimethadione, quinacrine, phenylbutazone), ionizing radiation, and viral infections (including hepatitis viruses, HIV, EBV, and parvovirus B19). AA can also occur in association with conditions such as PNH, immune diseases (eosinophilic fasciitis, hyperimmunoglobulinemia), thymoma/thymic carcinoma, graft-versus-host disease in immunodeficiency, and pregnancy. Inherited marrow failure syndromes include Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, reticular dysgenesis, amegakaryocytic thrombocytopenia, familial aplastic anemias, and other nonhematologic syndromes (e.g., Down syndrome).
Diagnosis requires excluding other causes of pancytopenia and hypocellular marrow. Important differentials include bone marrow infiltration (lymphoma, carcinoma), myelofibrosis, severe infection, hypoplastic myelodysplastic syndrome, hypersplenism, and hairy cell leukemia. Workup centers on CBC with peripheral smear and bone marrow aspiration/biopsy, which typically shows a hypocellular marrow with marked reduction or absence of hematopoietic precursor cells; in pure red cell aplasia, only erythroid precursors are absent. Laboratory evaluation usually demonstrates pancytopenia, sometimes with macrocytosis and toxic granulation; early disease may show isolated cytopenias. Reticulocytopenia is common. Additional labs include LDH and haptoglobin to assess for hemolysis, nutritional studies (B12, folate, copper, zinc, ferritin) to rule out deficiencies, and viral serologies (hepatitis A/B/C, HIV, CMV, parvovirus, EBV) to identify contributory infections and guide management. Peripheral blood flow cytometry is used to rule out PNH. Imaging is not routinely required, but MRI (spin-echo) can show the high fat content of aplastic marrow and may be helpful in evaluating marrow disease.
Management begins with nonpharmacologic measures, especially stopping any suspected offending drugs or exposures. Acute care focuses on complications: neutropenic fever requires prompt empiric broad-spectrum antibiotics, and cytopenias are supported with platelet and PRBC transfusions as needed. In patients who may undergo allogeneic stem cell transplantation, frequent transfusions should be minimized when possible to reduce alloimmunization risk. Chronic management depends on severity: some patients can be observed with supportive care, but transfusion dependence or meeting SAA criteria requires definitive therapy, and HLA typing should be done early once SAA is confirmed.
Definitive therapy for SAA is either immunosuppressive therapy (IST) or allogeneic stem cell transplantation (SCT), chosen based on age, donor availability, comorbidities, and response. Traditionally, patients <40 years are treated with upfront allogeneic sct, while those>40 years start with IST; patients over 40 may proceed to SCT if there is suboptimal IST response after ~4 months. HLA-matched sibling donor SCT is potentially curative. For those without a matched sibling, IST has been standard, but newer evidence supports earlier use of matched unrelated donor (MUD) or haploidentical donor transplantation in selected patients, with haploidentical approaches using post-transplant cyclophosphamide offering the potential for reduced GVHD and infections. Standard IST in patients <60 years commonly uses antithymocyte globulin (atg) plus cyclosporine, with atg reserved for fitter older patients lower comorbidity burden. ist is now routinely combined eltrombopag (an oral thrombopoietin receptor agonist) to improve platelet recovery in newly diagnosed patients. hematopoietic growth factors such as g-csf have not shown improved survival even long-term follow-up. who fail initial may proceed allogeneic sct or receive alternative immunosuppression alemtuzumab; other agents like corticosteroids and cyclophosphamide supportive roles, androgens (e.g., danazol) can be effective second-line options.< />pan>
Prognosis has improved substantially with modern therapy. Reported outcomes show 10-year survival after SCT (2000–2010 cohort) around 86% (<20 years), 76% (21-40 and 55% (>40 years). Newer transplant data also suggest improved survival in patients >50 years, especially with good performance status and matched sibling donors, though patients >65 years have higher rates of severe GVHD. With IST alone, about 50% achieve long-term remissions without relapse, but 10–20% may develop clonal evolution to secondary myelodysplasia or acute myeloid leukemia over ~10 years. Because transplant outcomes continue to improve, earlier use of SCT is increasingly recommended for more patients when feasible. All patients with suspected or confirmed aplastic anemia should be referred to hematology.
0 Comments
